UVI5008: the first reversible, non-covalent Bruton’s tyrosine kinase epi-inhibitor for B-cell malignancies
UVI5008 represents a promising pharmacological alternative to current BTK inhibitors. As the first-in-class, non-covalent, reversible, BTK inhibitor and epi-inhibitor of expression. UV15008 demonstrates potent in vitro anti-tumor efficacy in relapsed/refractory CLL cells, including cases with the C481S BTK mutation and in in vivo animal studies.
Authors
- Federico Chiurazzi
- Giulia Sgueglia (ORCID: https://orcid.org/0000-0002-7316-3375)
- Federica Sarno (ORCID: https://orcid.org/0000-0003-1871-1807)
- Michela Frenquelli (ORCID: https://orcid.org/0000-0003-4166-0438)
- Rosana Álvarez (ORCID: https://orcid.org/0000-0001-5608-7561)
- Jessica Bordini (ORCID: https://orcid.org/0000-0002-2669-6953)
- Davide Nappi (ORCID: https://orcid.org/0000-0001-9776-5875)
- Crescenzo Massaro (ORCID: https://orcid.org/0000-0002-1378-2086)
- Carmela Dell’Aversana (ORCID: https://orcid.org/0000-0001-6588-698X)
- Mariarosaria Conte (ORCID: https://orcid.org/0000-0002-3622-1476)
- Vincenzo Carafa
- Lucia Altucci
- F. P. Tambaro
- A. Campanella
- W. L. Megchelenbrink
- U. Perricone
- V. B. Petrizzi
- P. Ghia
- A. R. de Lera
- W. G. Wierda
Institutions
- Libera Università Maria SS. Assunta (IT)
- University Medical Center Groningen (NL)
- The University of Texas MD Anderson Cancer Center (US)
- Vita-Salute San Raffaele University (IT)
- University of Groningen (NL)
- University of Campania "Luigi Vanvitelli" (IT)
- Biogem (IT)
- CTO Andrea Alesini (IT)
- Federico II University Hospital (IT)
- Santobono Children's Hospital (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Institute for Experimental Endocrinology and Oncology (IT)
- Ri.MED (IT)
- Universidade de Vigo (ES)
Publication Details
- Journal
- Journal of Hematology & Oncology
- Published
- 2026-02-22
- DOI
- https://doi.org/10.1186/s13045-026-01784-9
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00